After writing her second novel, The Price of Salt—later adapted as Carol—publishers warned Patricia Highsmith that writing a “lesbian pulp novel” would kill her career before it had even begun.

It’s a New Year, and one of the best ways to get through the post-holiday blues and the lack of daylight is to take a deep dive into one of the best film genres out there. Crime movies cover a vast ...

In her filing, Patricia reportedly stated that the marriage is “irretrievably broken” with no possibility of reconciliation. She also indicated that the couple is in the process of negotiating ...

Comedian Rob Schneider and his wife, Patricia Azarcoya Schneider, are divorcing after 15 years of marriage. Patricia Azarcoya Schneider filed for divorce in Arizona, citing the marriage as ...

Rob Schneider’s wife, Patricia Azarcoya Schneider, has filed for divorce after 15 years of marriage, according to court documents filed in Maricopa County, Ariz., on Dec. 8. Patricia, 37, cited that ...

While the rising popularity of GLP-1s helps people to lose weight, the trend also puts Planet Fitness in a position to make gains, according to Stifel. The investment firm reiterated its buy rating on ...

Long held up as the big benchmark of nutrition, the calorie is losing its clout in the age of GLP-1s and a sharper focus on nutrients. Long held up as the big benchmark of nutrition, the calorie is ...

Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format. Reading time 3 minutes Novo Nordisk’s Ozempic kicked off the GLP-1 craze when it ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Bunnie Xo is no longer taking the injectable weight loss drug Retatrutide after a scary side effect that she says could have cost her her life. The podcaster and social media personality shared her ...

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...